Yellow Fever Vaccine Information

Yellow Fever Vaccine Information

Sanofi Pasteur’s new state-of-the-art YF-VAX® (Yellow Fever Vaccine) production facility has been licensed by the U.S. FDA and the transition of production continues. We are currently reassessing the YF-VAX return to supply timing and will provide an update by the end of 2019. In the interim, Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the U.S. through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in more than 70 countries. However, it is considered investigational in the U.S., as it is not a U.S.-licensed product.

The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, more than 250 geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.

Health care providers and patients may find locations that can administer STAMARIL vaccine by visiting the CDC web page at Due to increased demand for STAMARIL vaccine, supplies are temporarily limited resulting in allocations to provide continued access to yellow fever vaccine. When seeking yellow fever immunization, allow enough time to schedule an appointment at a STAMARIL clinic before travel. STAMARIL vaccine availability should improve by mid-summer of 2019.

Providers and patients may also visit for information about which countries require yellow fever vaccination for entry and for which countries the CDC recommends yellow fever vaccination.


YF-VAX vaccine is given to people 9 months of age and older who are at increased risk for yellow fever to help prevent them from getting the disease.

For more information about YF-VAX vaccine, talk to your health care professional.


YF-VAX vaccine should not be given to an individual who has experienced a serious allergic reaction to eggs, egg products, or to any component of the vaccine (including gelatin). A severe allergic reaction (eg, anaphylaxis) may occur following the use of YF-VAX vaccine, even in individuals with no prior history of hypersensitivity to the vaccine components.

In addition, the following persons should not receive YF-VAX vaccine: infants younger than 9 months of age, women who are breastfeeding infants younger than 9 months of age, and individuals with a severely suppressed or compromised immune system. Rarely, the yellow fever vaccine has been associated with disease affecting multiple organs, including inflammation of the brain.

The most common side effects to YF-VAX vaccine include swelling and pain at the injection site; headache, generalized muscle aches or discomfort, and fever. Other side effects may occur. Vaccination with YF-VAX vaccine may not protect all individuals.

Please see Full Prescribing Information for YF-VAX vaccine.

Please see the CDC Vaccine Information statement for Yellow Fever Vaccine.

Please see Full STAMARIL Patient Leaflet.